Tag: healthcare
-
Johnson & Johnson (JNJ) increases dividend by 4.2%, its 62nd consecutive annual increase
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate…
-
Abbvie announces 4.7% dividend increase
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023. “We delivered another quarter of outstanding results driven by accelerating performance across our non-Humira growth platform, which is demonstrating double-digit growth,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “Based upon the strength and momentum of our business, we are once again…
-
J&J (JNJ) offers investors 7% discount on shares of spin-off Kenvue (KVUE)
Johnson & Johnson (JNJ) is offering its shareholders a chance to swap some of their shares for KVUE (KVUE), the consumer health business it spun off in May 2023. KVUE is a stable and predictable company with well-known brands and a higher dividend yield than J&J. The exchange is tax-free and gives investors a 7%…
-
Johnson & Johnson raises dividend 5.3% its 61st consecutive dividend increase
Johnson & Johnson today announced that its Board of Directors has declared a 5.3% increase in the quarterly dividend, from $1.13 per share to $1.19 per share. “In recognition of our 2022 results, strong financial position, and confidence in the future of Johnson & Johnson, the Board of Directors has voted to increase the quarterly…
-
Johnson & Johnson proposes $9 billion settlement in talc case
As an investor of J&J I would like to see this approved and get the company past this. Johnson & Johnson has proposed paying at least $8.9 billion to thousands of people who sued the company alleging that their use of J&J’s talc-containing powders caused cancer, in what would be one of the biggest product-liability settlements ever.…
-
AbbVie looks to new drugs amidst increased competition for Humira
Now that its blockbuster immune-disease therapy Humira is facing lower priced competition, AbbVie is turning to a pair of next-generation successors to replenish the billions of dollars in sales that will be lost, Chief Executive Richard Gonzalez said. It is also betting on four drug approvals by the end of next year. In addition, AbbVie is lifting a self-imposed…